<DOC>
	<DOCNO>NCT00927862</DOCNO>
	<brief_summary>The purpose study determine whether DNA analysis improve efficiency dose safety patient start warfarin therapy.Warfarin , blood thinner ( anticoagulant ) prescribe 1-2 million patient United States , lead cause drug-related adverse event ( e.g. , severe bleeding ) , large part due dramatic ( 20-fold ) difference individual dose requirement . At least half variability explain 3 common genetic variant , age , body size , sex ; however , warfarin therapy continue begin dose every patient correct individual dose determine trial error . This study propose determine genetic variation day DNA simply obtain swab inside cheek use information determine proper dose regimen individually patient . The aim show investigator achieve rapid , efficient , safe dose 500-1000 individual initiate warfarin therapy various clot disorder across large healthcare system order demonstrate improve dose effectiveness , efficiency , safety genetic-based dosing , could lead nationwide application result much $ 1 billion dollar annual benefit healthcare outcome .</brief_summary>
	<brief_title>Applying Pharmacogenetic Algorithms Individualize Dosing Warfarin</brief_title>
	<detailed_description>Study Objectives : The specific objectives CoumaGen-II test : 1 . To apply routine pharmacogenetic ( PG ) -guided dose warfarin clinical practice Intermountain Healthcare facility Urban Central Region ( i.e. , Intermountain Medical Center [ IMC ] , LDS Hospital , Alta View Hospital [ AVH ] ) , select physician office frequent initiator warfarin ) major new quality improvement clinical research initiative . 2 . To compare percentage out-of-range ( % OOR ) international normalized prothrombin time ratio ( INRs ) first month ( secondarily , 3 month ) warfarin therapy use PG-guided dosing parallel historical standard ( STD ) , empiric dose control . 3 . To compare modify PG-guided dosing algorithm ( modified-International Warfarin Pharmacogenetics Consortium [ IWPC ] ) previously generate validate , multicenter PG-guided algorithm ( IWPC ) . Study Design : Qualifying patient initiate warfarin therapy target INR 1.5-2.5 , 2-3 , 2.5-3.5 invited participate sign inform consent . Enrolled patient receive DNA sample buccal swab , sample process PG-guided initial dose calculate goal &lt; 6 hour ( maximum , 24 hour ) . Dosing dose adjustment manage Urban Central Region ( IMC/LDSH ) anticoagulation management service ( AMS ) . Dose adjustment day 8 use PG-modified algorithm , modification revert standard IHC algorithm . AMS pharmacists study coordinator ascertain warfarin dos , INRs , dose change , adverse event , record information case report form . Study Duration : Each patient participate approximately 3 month ( 90 day Â± 10 day ) . The anticipated enrollment period 24 month 1000 patient enrol . The length enrollment period subject revision dependent availability robust patient pool . Further study detail dose algorithm genotyping methodology may provide Intermountain Healthcare Inc .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>New participant &gt; =18 year old appropriate candidate initiate warfarin therapy target international normalized prothrombin time ratio ( INR ) range either 23 2.53.5 intent treat least 1 month willing sign inform consent . Those target INR 2.53.5 may enrol dose adjustment high target per Gage etal . ( i.e. , 11 % increase dose ) . Dose modification also make amiodarone base prior , publish experience ( i.e. , 22 % decrease dose ) . Those appropriate warfarin ( e.g. , pregnancy ) pharmacogenetic ( PG ) guide dose reason , Those receive rifampin within 3 week , Those severe comorbidities ( e.g. , creatinine &gt; 2.5 , hepatic insufficiency , active malignancy , advance physiological age , noncompliance risk , expect survival &lt; 6 month ) , Physician patient preference .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>warfarin metabolism</keyword>
	<keyword>CYP2C9</keyword>
	<keyword>genotyping</keyword>
	<keyword>VKORC1</keyword>
	<keyword>anticoagulation</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>Patients initiate warfarin thromboembolic condition</keyword>
</DOC>